Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Receivables: 2019-2024

Historic Change in Receivables for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $5.4 million.

  • GeneDx Holdings' Change in Receivables rose 3.51% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 254.35%. This contributed to the annual value of $5.4 million for FY2024, which is 152.82% up from last year.
  • Latest data reveals that GeneDx Holdings reported Change in Receivables of $5.4 million as of FY2024, which was up 152.82% from -$10.3 million recorded in FY2023.
  • GeneDx Holdings' 5-year Change in Receivables high stood at $10.6 million for FY2020, and its period low was -$10.3 million during FY2023.
  • For the 3-year period, GeneDx Holdings' Change in Receivables averaged around -$3.5 million, with its median value being -$5.5 million (2022).
  • Per our database at Business Quant, GeneDx Holdings' Change in Receivables slumped by 152.16% in 2021 and then skyrocketed by 152.82% in 2024.
  • Over the past 5 years, GeneDx Holdings' Change in Receivables (Yearly) stood at $10.6 million in 2020, then plummeted by 152.16% to -$5.5 million in 2021, then climbed by 0.14% to -$5.5 million in 2022, then slumped by 85.69% to -$10.3 million in 2023, then soared by 152.82% to $5.4 million in 2024.